Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months

INTRODUCTION: Glaucoma is a leading cause of irreversible blindness and ripasudil was the first Rho kinase inhibitor approved as antiglaucoma medication. Here we present the final analysis of the ROCK-J study, a large-scale post-marketing surveillance study to evaluate the long-term safety and effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanihara, Hidenobu, Kakuda, Takahiko, Sano, Tetsuro, Kanno, Takashi, Kurihara, Yuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989847/
https://www.ncbi.nlm.nih.gov/pubmed/35150417
http://dx.doi.org/10.1007/s12325-021-02023-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989847/
https://www.ncbi.nlm.nih.gov/pubmed/35150417
http://dx.doi.org/10.1007/s12325-021-02023-y

Ejemplares similares